Drug sec­tor warns pa­tients will be de­nied new ther­a­pies

Kathimerini English - - Front Page -

Rep­re­sen­ta­tives of the phar­ma­ceu­ti­cal in­dus­try have ap­pealed to the Health Min­istry not to pro­ceed with leg­is­la­tion that they say will limit ac­cess to new ther­a­pies.

Ac­cord­ing to the Hel­lenic As­so­ci­a­tion of Phar­ma­ceu­ti­cal Com­pa­nies (SFEE), the new leg­is­la­tion, to be sub­mit­ted to Par­lia­ment in the com­ing days, will stip­u­late that a new drug can only be dis­trib­uted on the Greek mar­ket if it re­ceives a pos­i­tive Health Tech­nol­ogy As­sess­ment (HTA) in six Euro­pean Union coun­tries – name- ly the UK, France, Italy, Por­tu­gal, Swe­den and Spain. HTA is the sys­tem­atic eval­u­a­tion of the prop­er­ties and ef­fects of a health tech­nol­ogy.

SFEE pres­i­dent Akis Apos­tolides said the pro­posed mea­sures will hin­der the ac­cess of pa­tients to “in­no­va­tive ther­a­pies” as their in­tro­duc­tion to Greece will be de­layed by two to four years or even more.

On av­er­age, it takes roughly 21 months be­fore a new drug is ap­proved and al­lowed on the Greek mar­ket, while in the EU the av­er­age time is 3.9 months.

Newspapers in English

Newspapers from Greece

© PressReader. All rights reserved.